Mayinglong Pharmaceutical Group Co Ltd
Mayinglong Pharmaceutical Group Co., Ltd., together with its subsidiaries, manufactures and sells Chinese and Western medicines in China and internationally. The company offers functional cosmetics, functional care products and food, Chinese herbal medicines, and medical devices. It also manufactures, processes, and sells medicinal packaging materials, cosmetics, and Chinese medicines; and offers… Read more
Mayinglong Pharmaceutical Group Co Ltd (600993) - Net Assets
Latest net assets as of September 2025: CN¥4.43 Billion CNY
Based on the latest financial reports, Mayinglong Pharmaceutical Group Co Ltd (600993) has net assets worth CN¥4.43 Billion CNY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥5.34 Billion) and total liabilities (CN¥909.82 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥4.43 Billion |
| % of Total Assets | 82.97% |
| Annual Growth Rate | 14.9% |
| 5-Year Change | 42.58% |
| 10-Year Change | 122.7% |
| Growth Volatility | 27.25 |
Mayinglong Pharmaceutical Group Co Ltd - Net Assets Trend (2001–2024)
This chart illustrates how Mayinglong Pharmaceutical Group Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Mayinglong Pharmaceutical Group Co Ltd (2001–2024)
The table below shows the annual net assets of Mayinglong Pharmaceutical Group Co Ltd from 2001 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥4.20 Billion | +8.56% |
| 2023-12-31 | CN¥3.87 Billion | +6.94% |
| 2022-12-31 | CN¥3.62 Billion | +9.19% |
| 2021-12-31 | CN¥3.31 Billion | +12.48% |
| 2020-12-31 | CN¥2.95 Billion | +11.83% |
| 2019-12-31 | CN¥2.63 Billion | +12.04% |
| 2018-12-31 | CN¥2.35 Billion | +3.56% |
| 2017-12-31 | CN¥2.27 Billion | +12.60% |
| 2016-12-31 | CN¥2.02 Billion | +6.91% |
| 2015-12-31 | CN¥1.89 Billion | +11.05% |
| 2014-12-31 | CN¥1.70 Billion | +8.46% |
| 2013-12-31 | CN¥1.57 Billion | +9.28% |
| 2012-12-31 | CN¥1.43 Billion | +8.59% |
| 2011-12-31 | CN¥1.32 Billion | +17.10% |
| 2010-12-31 | CN¥1.13 Billion | +7.18% |
| 2009-12-31 | CN¥1.05 Billion | +20.69% |
| 2008-12-31 | CN¥871.43 Million | +2.15% |
| 2007-12-31 | CN¥853.12 Million | -0.24% |
| 2006-12-31 | CN¥855.21 Million | +43.36% |
| 2005-12-31 | CN¥596.55 Million | +8.03% |
| 2004-12-31 | CN¥552.20 Million | +138.69% |
| 2003-12-31 | CN¥231.35 Million | +13.11% |
| 2002-12-31 | CN¥204.54 Million | +18.91% |
| 2001-12-31 | CN¥172.01 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Mayinglong Pharmaceutical Group Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 6599.6% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥3.31 Billion | 81.48% |
| Common Stock | CN¥431.05 Million | 10.60% |
| Other Comprehensive Income | CN¥299.76 Million | 7.37% |
| Other Components | CN¥22.02 Million | 0.54% |
| Total Equity | CN¥4.07 Billion | 100.00% |
Mayinglong Pharmaceutical Group Co Ltd Competitors by Market Cap
The table below lists competitors of Mayinglong Pharmaceutical Group Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Faw Car Co Ltd
SHE:000800
|
$987.62 Million |
|
Bayer Cropscience Limited
NSE:BAYERCROP
|
$988.05 Million |
|
Waypoint REIT
AU:WPR
|
$988.11 Million |
|
Sunonwealth Electric Machine Industry Co Ltd
TW:2421
|
$988.16 Million |
|
Sinodata Co Ltd
SHE:002657
|
$987.43 Million |
|
Shanghai Bailian Group Co Ltd A
SHG:600827
|
$987.40 Million |
|
Srisawad Corporation Public Company Limited
BK:SAWAD-R
|
$987.24 Million |
|
Fincantieri S.p.A
PINK:FNCNF
|
$987.15 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Mayinglong Pharmaceutical Group Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 3,737,968,219 to 4,065,961,926, a change of 327,993,707 (8.8%).
- Net income of 528,093,863 contributed positively to equity growth.
- Dividend payments of 177,280,794 reduced retained earnings.
- Other comprehensive income increased equity by 297,678.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥528.09 Million | +12.99% |
| Dividends Paid | CN¥177.28 Million | -4.36% |
| Other Comprehensive Income | CN¥297.68K | +0.01% |
| Other Changes | CN¥-23.12 Million | -0.57% |
| Total Change | CN¥- | 8.77% |
Book Value vs Market Value Analysis
This analysis compares Mayinglong Pharmaceutical Group Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.79x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 77.58x to 2.79x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2001-12-31 | CN¥0.34 | CN¥26.27 | x |
| 2002-12-31 | CN¥0.41 | CN¥26.27 | x |
| 2003-12-31 | CN¥0.47 | CN¥26.27 | x |
| 2004-12-31 | CN¥1.21 | CN¥26.27 | x |
| 2005-12-31 | CN¥1.30 | CN¥26.27 | x |
| 2006-12-31 | CN¥1.42 | CN¥26.27 | x |
| 2007-12-31 | CN¥1.67 | CN¥26.27 | x |
| 2008-12-31 | CN¥1.83 | CN¥26.27 | x |
| 2009-12-31 | CN¥2.21 | CN¥26.27 | x |
| 2010-12-31 | CN¥2.38 | CN¥26.27 | x |
| 2011-12-31 | CN¥2.71 | CN¥26.27 | x |
| 2012-12-31 | CN¥2.97 | CN¥26.27 | x |
| 2013-12-31 | CN¥3.30 | CN¥26.27 | x |
| 2014-12-31 | CN¥3.66 | CN¥26.27 | x |
| 2015-12-31 | CN¥4.16 | CN¥26.27 | x |
| 2016-12-31 | CN¥4.50 | CN¥26.27 | x |
| 2017-12-31 | CN¥5.07 | CN¥26.27 | x |
| 2018-12-31 | CN¥5.28 | CN¥26.27 | x |
| 2019-12-31 | CN¥5.93 | CN¥26.27 | x |
| 2020-12-31 | CN¥6.61 | CN¥26.27 | x |
| 2021-12-31 | CN¥7.36 | CN¥26.27 | x |
| 2022-12-31 | CN¥8.11 | CN¥26.27 | x |
| 2023-12-31 | CN¥8.69 | CN¥26.27 | x |
| 2024-12-31 | CN¥9.43 | CN¥26.27 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Mayinglong Pharmaceutical Group Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 12.99%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 14.17%
- • Asset Turnover: 0.72x
- • Equity Multiplier: 1.27x
- Recent ROE (12.99%) is below the historical average (13.74%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2001 | 18.60% | 13.44% | 0.64x | 2.17x | CN¥12.74 Million |
| 2002 | 18.48% | 13.28% | 0.68x | 2.04x | CN¥15.11 Million |
| 2003 | 19.42% | 12.22% | 0.89x | 1.80x | CN¥19.30 Million |
| 2004 | 9.96% | 14.19% | 0.54x | 1.29x | CN¥-190.62K |
| 2005 | 10.55% | 14.59% | 0.53x | 1.36x | CN¥3.13 Million |
| 2006 | 11.89% | 13.35% | 0.49x | 1.83x | CN¥11.40 Million |
| 2007 | 18.57% | 24.32% | 0.50x | 1.52x | CN¥61.55 Million |
| 2008 | 10.30% | 9.93% | 0.70x | 1.49x | CN¥2.37 Million |
| 2009 | 18.93% | 17.62% | 0.71x | 1.51x | CN¥84.94 Million |
| 2010 | 11.98% | 10.40% | 0.81x | 1.42x | CN¥20.23 Million |
| 2011 | 11.94% | 9.83% | 0.85x | 1.44x | CN¥22.40 Million |
| 2012 | 13.47% | 11.27% | 0.84x | 1.43x | CN¥44.74 Million |
| 2013 | 13.07% | 11.63% | 0.79x | 1.42x | CN¥43.74 Million |
| 2014 | 12.83% | 12.43% | 0.74x | 1.39x | CN¥44.43 Million |
| 2015 | 12.51% | 12.52% | 0.74x | 1.35x | CN¥44.85 Million |
| 2016 | 12.90% | 11.90% | 0.84x | 1.29x | CN¥56.22 Million |
| 2017 | 14.60% | 18.28% | 0.64x | 1.26x | CN¥100.83 Million |
| 2018 | 7.76% | 8.02% | 0.75x | 1.29x | CN¥-50.87 Million |
| 2019 | 14.08% | 13.31% | 0.82x | 1.28x | CN¥104.27 Million |
| 2020 | 14.71% | 15.01% | 0.72x | 1.36x | CN¥134.12 Million |
| 2021 | 14.65% | 13.72% | 0.82x | 1.30x | CN¥147.45 Million |
| 2022 | 13.69% | 13.55% | 0.70x | 1.45x | CN¥128.95 Million |
| 2023 | 11.86% | 14.13% | 0.65x | 1.29x | CN¥69.45 Million |
| 2024 | 12.99% | 14.17% | 0.72x | 1.27x | CN¥121.50 Million |
Industry Comparison
This section compares Mayinglong Pharmaceutical Group Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $4,523,155,599
- Average return on equity (ROE) among peers: -21.03%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Mayinglong Pharmaceutical Group Co Ltd (600993) | CN¥4.43 Billion | 18.60% | 0.21x | $987.44 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $52.15 Million | 21.80% | 0.58x | $623.66 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $765.24 Million | 1.30% | 0.72x | $325.92 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $78.32 Million | 0.00% | 1.98x | $3.03 Billion |
| Wedge Industrial Co Ltd (000534) | $1.24 Billion | 8.20% | 0.96x | $1.75 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $38.34 Billion | 14.39% | 0.44x | $5.59 Billion |
| Hainan Haiyao Co Ltd (000566) | $590.38 Million | -258.34% | 9.36x | $713.60 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $184.11 Million | -46.59% | 2.19x | $317.60 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $1.57 Billion | 22.73% | 1.61x | $426.40 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $2.06 Billion | 23.61% | 0.46x | $2.04 Billion |
| Renhe Pharmacy Co Ltd (000650) | $338.74 Million | 2.59% | 1.24x | $777.45 Million |